Photo of a veterinarian examining a grey cat in a clinic
Dr. Casey Robinson
Words by:
Casey Robinson, DVM — Director of Clinical Excellence, Mid-Atlantic & Upper Midwest

Why this study matters

In a new double-blinded JAVMA trial, no male cats on oral lorazepam re-obstructed in the 30 days after their first urethral obstruction, compared with about 16% of cats on placebo.

Anyone who has unblocked a cat, or managed one with FLUTD, knows the hardest part often comes after discharge. Recurrence is common, usually within the first few weeks, and it is a leading reason owners choose euthanasia or perineal urethrostomy. Prazosin hasn’t reduced recurrence in prospective studies, and one large retrospective study linked it to more recurrence.

At our October IndeVets Virtual Journal Club, our doctors worked through this paper together. Here is what we found, what we questioned, and what it might mean for your next blocked cat.

How the study was built

Researchers at the University of Minnesota enrolled 80 male cats presenting with a first-time urethral obstruction. Cats with uroliths, urinary tract infection, chronic kidney disease, or a previous obstruction were excluded.

  • Design: prospective, randomized, double-blinded, and placebo-controlled.
  • Treatment: lorazepam 0.25 mg per cat (about 0.05 mg/kg) PO q12h, or placebo, for 30 days.
  • Discharge plan: every cat went home with buprenorphine, a prescription urinary diet, and environmental modification guidance. Nearly all also received gabapentin.

Owners judge urinary signs at home, so keeping them blinded removes a real source of bias.

What they found

Seventy-two cats completed the study, and the results favored lorazepam on the outcome that matters most.

  • No cat on lorazepam re-obstructed. Five placebo cats (15.7%) did, and 3 of those owners chose perineal urethrostomy.
  • Urinary signs dropped after the first week. Both groups had signs in week one, likely from catheter irritation. From day 8 on, only 3% to 6% of lorazepam cats had signs, compared with 22% to 29% on placebo. Over the full 30 days, the difference fell just short of statistical significance.
  • Ataxia was the only side effect clearly linked to lorazepam, seen in about 1 in 8 cats. Sedation, increased appetite, and vocalization were reported somewhat more often, but not significantly. No excitement or aggression was reported. It is possible that the multi-modal treatment approach exacerbated the suspected lorazepam-induced ataxia.
  • Two cats were withdrawn over adverse effects: one with pacing and drooling after dosing, and one with a preexisting neuropathy that could have clouded neurologic exams.

Why lorazepam might work

The distal male urethra, where most plugs lodge, is mostly skeletal muscle. Prazosin and phenoxybenzamine relax smooth muscle, so they may be aimed at the wrong segment. Lorazepam relaxes skeletal muscle and also reduces stress, which plays a role in feline idiopathic cystitis.

It’s also a better benzodiazepine choice than diazepam. Oral diazepam has been linked to fatal hepatic necrosis in cats, but cats metabolize lorazepam efficiently and without the intermediate metabolites thought to cause hepatocellular injury.

What our journal club questioned

The group liked this paper, and we also raised three questions worth keeping in mind.

Liver values weren’t tracked. Lorazepam’s metabolism makes hepatotoxicity unlikely, but chemistry profiles weren’t required, so ALT and ALKP weren’t monitored. We’d like to see that data before a month-long benzodiazepine course becomes routine. In the acute phase, based on the physiologic metabolism of this drug, it is likely safe.

Gabapentin was in the mix. It causes sedation and ataxia too, and the authors note it may have contributed to the ataxia finding.

The placebo group did better than expected. Placebo recurrence was lower than in earlier studies, possibly because every cat got diet and environmental support. If so, lorazepam’s added benefit may be smaller than the headline suggests.

The authors add their own caveats. The study closed early at 80 cats with only 5 recurrences, hospital care varied by clinician, and the optimal dose is unknown. They call for larger multicenter trials.

The takeaway for your next shift

Lorazepam appears to be an effective and well-tolerated option for preventing recurrence in the 30 days after a cat’s first obstruction, and it may reduce urinary signs after the first week. It isn’t proven yet, but it is the most encouraging recurrence result we’ve seen.

If you’re considering it in practice:

  • Use it in cats like those studied: male, first obstruction, with uroliths, UTI, and CKD ruled out.
  • The study dose was 0.25 mg per cat PO q12h for 30 days.
  • Avoid it in cats with a history of benzodiazepine sensitivity.
  • Prepare owners for ataxia and sedation, especially alongside gabapentin.
  • Consider baseline and follow-up liver values until more safety data are available.
  • Keep the fundamentals in place: diet, water intake, environmental enrichment, pain control and stress reduction.

As relief doctors, we often discharge a lower urinary tract patient without being there for the recheck. Clear home instructions and a documented plan for the regular team make a new protocol like this one safer to use.

Join the conversation

Our doctors meet for IndeVets Virtual Journal Club to work through new literature together, always asking what a paper means for the patient in front of us. It’s one of the ways we keep building clinical skills, with peers and clinical leaders, as we work across hospitals. Curious what practicing with that kind of support looks like? Join us for our next webinar.

 

Sources

Splittstoesser A, Kerley J, Lulich J, Randall A, Tart K. Lorazepam reduces recurrence of urethral obstruction in male cats: a prospective, randomized, double-blinded, placebo-controlled study. J Am Vet Med Assoc. 2026;264(9):1143-1151. doi:10.2460/javma.26.01.0045